← All trials
NCT05786066
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 3, 2023
- Primary completion
- Mar 31, 2033
- Completion date
- Mar 31, 2033
- First posted
- Mar 27, 2023
- Last posted
- Sep 13, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- American Foundation for Suicide PreventionCollaborator
- National Center for PTSDCollaborator
- Department of Veteran AffairsCollaborator
- Yale UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.